In the phase III IMmotion151 trial of metastatic renal cell carcinoma the easy-to-implement modified Glasgow prognostic score predicts outcome more accurately than the IMDC score

Affiliations

• ¹ Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Medical Center Bonn (UKB), Bonn;; Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn;; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn.
• ² Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn;; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn;. Electronic address: https://twitter.com/Doc_Bald.
• ³ Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn;; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn;. Electronic address: https://twitter.com/HolzelMichael.
• ⁴ Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn;; Department of Urology and Pediatric Urology, University Medical Center Bonn (UKB), Bonn, Germany.
• ⁵ Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Medical Center Bonn (UKB), Bonn;; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn.
• ⁶ Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn;; Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn;; Department of Urology and Pediatric Urology, University Medical Center Bonn (UKB), Bonn, Germany. Electronic address: [email protected].